Company Overview More
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company’s enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
CEO: Baxter F.C.M.A., FCMA, Jeffery R.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

VBIV VBI Vaccines
1.040-0.040-3.70%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-24.13% 101.34M 2.18% 121.69M 2.18% 121.69M 14.2% 137.47M
-Cash and cash equivalents
-6.37% 101.34M 29.7% 121.69M 29.7% 121.69M 44.46% 137.47M
-Short-term investments
-- -- -- 0 -- 0 -- 0
Receivables
-54.2% 2.87M -81.71% 1.45M 1777.92% 1.45M 10603.7% 2.89M
-Accounts receivable
-40.7% 102K -89.61% 8K -89.61% 8K 33.33% 36K
-Other receivables
-54.58% 2.77M -81.63% 1.44M -- 1.44M -- 2.85M
Inventory
87.39% 4.06M 19.7% 2.58M 19.7% 2.58M 46.89% 2.27M
Prepaid assets
99.54% 2.17M 51.24% 2.37M -77.85% 2.37M 33.06% 3.05M
Other current assets
-22.81% 1.92M 67.3% 2.2M -- 2.2M -1.21% 2.13M
Total current assets
-22.82% 112.35M -1.33% 130.28M -1.33% 130.28M 16.94% 147.8M
Non current assets
Net PPE
27.36% 14.69M 17.16% 14.38M 34.14% 14.38M -2.68% 10.92M
-Gross PPE
27.36% 14.69M 21.75% 19.34M -- 19.34M -2.68% 10.92M
-Accumulated depreciation
-- -- -37.37% -4.96M -- -4.96M -- --
Goodwill and other intangible assets
0.77% 65.52M -0.1% 64.35M -0.1% 64.35M 5.04% 64.41M
-Goodwill
0.88% 2.3M 0% 2.26M 0% 2.26M 5.16% 2.26M
-Other intangible assets
0.77% 63.22M -0.1% 62.09M -0.1% 62.09M 5.04% 62.15M
Other non current assets
84.91% 1.45M 97.03% 1.26M -42.59% 1.26M 75.88% 1.09M
Total non current assets
5.59% 81.66M 3.44% 79.99M 3.44% 79.99M 4.46% 76.43M
Total assets
-12.96% 194.01M 0.43% 210.28M 0.43% 210.28M 12.36% 224.23M
Liabilities
Current liabilities
Payables
135.43% 3.93M 14.62% 4.28M 14.62% 4.28M 11.59% 3.75M
-accounts payable
135.43% 3.93M 14.62% 4.28M 14.62% 4.28M 11.59% 3.75M
Current accrued expenses
31.8% 13.74M 36.16% 15.3M -- 15.3M 50.36% 13.48M
Current debt and capital lease obligation
542.03% 5.68M -11.12% 839K -11.12% 839K -51.89% 408K
-Current debt
-- 4.74M -- -- -- -- -- --
-Current capital lease obligation
5.99% 938K -11.12% 839K -11.12% 839K -51.89% 408K
Current deferred liabilities
-10.57% 9.31M 4099.61% 10.71M 4099.61% 10.71M 3544.36% 14.87M
Other current liabilities
201.35% 1.34M 23.77% 1.46M -88.22% 1.46M 19.68% 444K
Current liabilities
42.67% 33.99M 87.84% 32.59M 87.84% 32.59M 136.19% 32.95M
Non current liabilities
Long term debt and capital lease obligation
68.94% 27.71M 82.66% 30.96M -- 30.96M 68.34% 28.05M
-Long term debt
55.51% 24.79M 74.17% 28.44M -- 28.44M 76.14% 27.94M
-Long term capital lease obligation
532.25% 2.92M 306.46% 2.52M -- 2.52M -86.59% 107K
Non current deferred liabilities
2.36% 2.17M -20.08% 2.28M -- 2.28M -4.26% 2.54M
Employee benefits
5.9% 574K 9.96% 574K -- 574K 13.2% 549K
Total non current liabilities
59.75% 30.45M 66.39% 33.81M 66.39% 33.81M 57.26% 31.14M
Total liabilities
50.26% 64.44M 76.27% 66.39M 76.27% 66.39M 89.89% 64.08M
Shareholders'equity
Share capital
3.56% 442.27M 9.59% 442.24M -- 442.24M 13.3% 439.29M
-common stock
3.56% 442.27M 9.59% 442.24M -- 442.24M 13.3% 439.29M
Retained earnings
-21.85% -397.56M -22.6% -378.37M -- -378.37M -22.62% -359.59M
Paid-in capital
4.76% 81.31M 8.01% 81.58M -- 81.58M 6.74% 79.08M
Gains losses not affecting retained earnings
120.02% 3.54M -223.72% -1.57M -- -1.57M 150.04% 1.37M
Total stockholders'equity
-28.02% 129.56M -16.2% 143.88M -16.2% 143.88M -3.41% 160.14M
Total equity
-28.02% 129.56M -16.2% 143.88M -16.2% 143.88M -3.41% 160.14M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%